Stryker Corp  (SYK)
Other Ticker:  
Price: $275.5800 $4.09 1.507%
Day's High: $270.405 Week Perf: 1.11 %
Day's Low: $ 269.19 30 Day Perf: -8.11 %
Volume (M): 29 52 Wk High: $ 306.56
Volume (M$): $ 7,877 52 Wk Avg: $240.82
Open: $270.98 52 Wk Low: $188.84

 Market Capitalization (Millions $) 105,602
 Shares Outstanding (Millions) 383
 Employees 46,000
 Revenues (TTM) (Millions $) 18,952
 Net Income (TTM) (Millions $) 2,627
 Cash Flow (TTM) (Millions $) 213
 Capital Exp. (TTM) (Millions $) 599

Stryker Corp
Stryker Corporation'is a leader in the worldwide orthopaedic market and is one of the worlds largest medical device companies.'Stryker delivers results through a wide range of capabilities including joint replacements, trauma, spine and micro implant systems, orthobiologics, powered surgical instruments, surgical navigation systems and endoscopic products as well as patient handling and emergency medical equipment.'Stryker also provides outpatient physical therapy services in the United States.'Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a leading orthopaedic surgeon and the inventor of several orthopaedic products.

The Company segregates its operations into two reportable business segments: Orthopaedic Implants and MedSurg Equipment.'The Orthopaedic Implants segment sells orthopaedic reconstructive (hip, knee and shoulder), trauma and spinal implants, bone cement and the bone growth factor osteogenic protein-1 ("OP-1").' The MedSurg Equipment segment sells powered surgical instruments, endoscopic products, hospital beds and stretchers and micro implant and surgical navigation systems.'

Most of the Companys products and product improvements have been developed internally.'The Company maintains close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development.'New and improved products play a critical role in the Companys sales growth.'The Company continues to place emphasis on the development of proprietary products and product improvements to complement and expand its existing product lines.'The Company has a decentralized research and development focus, with manufacturing locations responsible for new product development and product improvements.'Research, development and engineering functions at the manufacturing locations maintain relationships with distribution locations and customers to understand changes in the market and product needs.

In the United States, most of the Companys products are marketed directly to more than 6,000 hospitals and to other health-care facilities and doctors by approximately 2,100 sales and marketing personnel.'Stryker primarily maintains separate and dedicated sales forces for each of its principal product lines to provide focus and a high level of expertise to each medical specialty served.

The Companys manufacturing processes consist primarily of precision machining, metal fabrication and assembly operations; the forging and investment casting of cobalt chrome; and the finishing of cobalt chrome and titanium.'In addition, the Company is the sole manufacturer of its OP-1 product.'The principal raw materials used by the Company are stainless steel, aluminum, cobalt chrome and titanium alloys.'


The Company is one of four leading competitors in the United States for orthopaedic reconstructive products.'The three other leading competitors are DePuy Orthopaedics, Inc. (a subsidiary of Johnson & Johnson), Zimmer Holdings, Inc., and Biomet, Inc. While competition abroad varies from area to area, the Company believes it is also a leading player in the international markets with these same companies as its principal competitors.

In the trauma implant segment, Stryker is one of five leaders competing principally with Synthes-Stratec, Smith & Nephew Orthopaedics (a division of Smith & Nephew plc), Zimmer Holdings, Inc., and DePuy Orthopaedics, Inc.

In the spinal implant segment, the Company is one of four leaders, including the principal competitors Medtronic SofamorDanek, Inc. (a subsidiary of Medtronic, Inc.), DePuyAcroMed, Inc. (a subsidiary of Johnson & Johnson), and Synthes-Stratec.

The Company believes that several companies are engaged in the research and development of morphogenic proteins for the repair of hard and soft tissues that would compete with the Companys OP-1 product.'Wyeth has completed human clinical trials of a recombinant bone morphogenetic protein ("rhBMP-2") for repair of orthopaedic and other skeletal defects and has awarded certain distribution rights to Medtronic SofamorDanek for rhBMP-2 in the United States and Europe.'A number of companies currently provide various other therapies, including allografts, bone fillers and electrical stimulation devices for the treatment, repair or replacement of bone and joint tissue.'The Company believes that its OP-1 product, which is approved for limited trauma indications in certain markets and is currently in clinical trials for other indications, would ultimately compete with these products and with traditional therapies, such as autograft.

In the powered surgical instruments segment, Stryker is one of three leaders, together with the principal domestic competitors Medtronic Midas Rex, Inc. (a subsidiary of Medtronic, Inc.), and Linvatec, Inc. (a subsidiary of CONMED Corporation).' These companies are also competitors in the international segments, along with Aesculap-Werke AG (a division of B. Braun Melsungen AG), a large European manufacturer.

In the arthroscopy segment, the Company is one of four leaders, together with the principal competitors Smith & Nephew Endoscopy (a division of Smith & Nephew plc), Linvatec, Inc., and Arthrex, Inc.'In the laparoscopic imaging products segment, the Company is one of four leaders, together with the principal competitors Karl Storz GmbH & Co. (a German company), ACMI Corporation and Olympus Optical Co. Ltd. (a Japanese company).

In the craniomaxillofacial segment, Stryker is one of four leaders, together with the principal competitors Synthes-Stratec, Walter Lorenz Surgical, Inc. (a subsidiary of Biomet, Inc.), and KLS Martin L.P.

In the surgical navigation segment, Stryker is one of five principal competitors including Medtronic Surgical Navigation Technologies (a division of Medtronic, Inc.), BrainLAB Inc. (a subsidiary of BrainLAB AG), AESCULAP AG & Co. KG (a division of B. Braun Melsungen AG), Radionics, Inc. (a subsidiary of Tyco International Ltd.), and GE Medical Systems Navigation and Visualization, Inc. (a subsidiary of General Electric Company).

The Companys primary competitor in the patient-handling segment is Hill-Rom Company, Inc. (a division of Hillenbrand Industries, Inc.).'In the specialty stretcher segment, the primary competitors are Hausted, Inc. (a subsidiary of STERIS Corporation), Hill-Rom Company, Inc., and Midmark Hospital Products Group (a subsidiary of Ohio Medical Instrument Company, Inc.).'In the ambulance cot segment, Ferno-Washington, Inc. is the Companys principal competitor.

In the United States outpatient physical and occupational rehabilitation segment, the Companys primary competitors are independent therapist-owned practices and hospital-based services, in addition to other national rehabilitation companies, including HEALTHSOUTH Corporation and NovaCare Rehabilitation (a division of Select Medical Corporation).

The principal factors that the Company believes differentiate it in these highly competitive market segments and enable it to compete effectively are innovation, reliability, service and reputation.'The Company is not able to predict the effect that continuing efforts to reduce health-care expenses generally and hospital costs in particular will have on the future sales of its products or its competitive position.'The Company believes that its competitive position in the future will depend to a large degree on its ability to develop new products and make improvements in existing products.'While the Company does not consider patents a major factor in its overall competitive success, patents and trademarks are significant to the extent that a product or attribute of a product represents a unique design or process.'Patent or trademark protection of such products restricts competitors from duplicating these unique designs and features.'Stryker seeks to obtain patent protection on its products whenever possible.'The Company currently has approximately 840 United States patents and 1,240 international patents.

   Company Address: 2825 Airview Boulevard Kalamazoo, 49002 MI
   Company Phone Number: 385-2600   Stock Exchange / Ticker: NYSE SYK
   SYK is expected to report next financial results on July 26, 2023. Next quarterly dividend pay out on August 02, 2023.

Customers Net Income grew by SYK's Customers Net Profit Margin grew to

189.57 %

2.1 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
BSX   -0.04%    
CAH   -2.94%    
DHR   -0.17%    
JNJ   -1.12%    
KNW   -0.8%    
MCK   -0.59%    
• View Complete Report

Delcath Systems Inc

Delcath Systems Inc announced the deficit has been cut back remarkably, over the January to March 31 2023 period

Investors, get ready to rejoice! Delcath Systems Inc has delivered some impressive results for the first quarter of 2023. The company reported a whopping 57.937% revenue growth to $0.60 million, which has effectively helped to bring down losses to $-0.77 per share. This is a significant improvement from the $-1.00 per share loss reported in the same quarter last year.
Despite a decline in revenue in Q4, it's worth noting that the company managed to improve its EPS from $-0.88 to $-0.77 per share in the most recent quarter. It's always a good indication when a company is able to cut losses and improve profitability.

Haemonetics Corporation

Breathtaking financial reporting period by at the Haemonetics Corporation during the February to April 01 2023 span

Investors in Haemonetics Corporation can expect solid growth and increased earnings based on the company's fiscal fourth quarter 2023 financial results. The medical equipment and supplies company reported an impressive 71.13% increase in income per share to $0.77 compared to the previous year, while revenues grew by 31.706% to $342.13 million.
The company's net earnings also saw a healthy increase of 69.37% to $39.348 million. Although operating margin fell to 13.54%, the net margin actually improved to 11.5%. Operating earnings, however, only improved by 29.97% to $46.336 million.

T2 Biosystems Inc

Extremely challenging financial reporting period for T2 Biosystems Inc during the financial period ending March 31 2023

While the stock market can be a turbulent place, there is one company that has had a rough start to 2023. T2 Biosystems Inc recently reported a substantial decrease in revenue, a net loss per share expansion, and a significant drop in sequential revenue, causing some investors to worry.
But let's take a closer look at what these numbers actually mean. While the Mar 31 2023 report was certainly a disappointment, it's important to remember that these are just one quarter's worth of financials. There are always ups and downs in the stock market, and companies often experience setbacks before bouncing back stronger than ever.

H Cyte Inc

The revenue are the similar like a year prior at the Medical Equipment and Supplies company over the January to March 31 2023 span

H Cyte Inc is a company involved in the developing and commercialization of medical therapeutics, specifically in the field of regenerative medicine. The company's focus is on developing therapies for joint and spine-related conditions. The company is headquartered in California and began trading on the NASDAQ Global Market in February 2022 under the ticker symbol HCYT.
In the first quarter of 2023, H Cyte Inc reported that its net deficit had expanded to $-3.38 per share, compared to $0.00 per share in the same period of the previous year. However, the company's EPS improved to $-5.08 per share from the previous reporting season. In terms of revenue, the company's earnings remained unchanged at $0.00 million from the previous year's reporting season and sequentially. The company also reported a net deficit of $-2.090 million in the first quarter of 2023, compared to a deficit of $-3.892 million in the same period of the previous year.

Therapeutic Solutions International Inc

Severe hit for Therapeutic Solutions International Inc all along the financial span ending March 31 2023

Therapeutic Solutions International Inc, a pharmaceutical company, recently published its fiscal interval report ending on March 31, 2023. The report indicated that the company was able to maintain balanced books, showing no earnings or losses per share. This is the same as the previous fiscal year, but an improvement from the previous reporting period.
The company's revenue, on the other hand, decreased by 72.764% from $0.08 million in the comparative period to $0.02 million. However, sequentially, there was a significant increase of 169.53% from $0.01 million. This indicates that the company's financial performance has been unstable overall.


Stryker's Segments
 Segment     of total Revenue
 Segment     of total Revenue
Trauma & Extremities
 Segment     of total Revenue
Total Reconstructive
 Segment     of total Revenue
Surgical equipment
 Segment     of total Revenue
Endoscopic & communications systems
 Segment     of total Revenue
Patient handling & emergency equipment
 Segment     of total Revenue
Total MedSurg
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Total Neurotechnology & Spine
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Stryker announced annual revenue outlook on

Earnings Outlook
Stryker Corp issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071